2/2
Autorzy: S[ilvia] Novello, G[iorgio] Scagliotti, R[odryg] Ramlau, A[dolfo] Favaretto, F[abrice] Barlesi, W[allace] Akerley, J[oachim] von Pawel, S[ergey] Orlov, D[avid] R. Spigel, A[rmando] Santoro, F[rances] Shepherd, V[era] Hirsh, L[ecia] V. Sequist, D[ale] Shuster, H[amim] Zahir, Q[iang] Wang, B[rian] Schwartz, R[einhard] von Roemeling, A[llan] B. Sandler. Tytuł: Efficacy analysis for molecular subgroups in marquee: a randomized, doubleblind, placebo-controlled, phase 3 trial of tivantinib (ARQ 197) plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small cell lung cancer (NSCLC). Czasopismo: J. Thoracic Oncol. Szczegóły: 2013 : Vol. 8, suppl. 2, s. S901-S902. Uwagi: 15th World Conference on Lung Cancer. Sydney, Australia, October 27-30, 2013. p-ISSN: 1556-0864 e-ISSN: 1556-1380 Typ publikacji: ZSZ Język publikacji: EN Polskie hasła przedmiotowe: